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Abstract
Background:  Anorexia nervosa is a serious eating disorder leading to high morbidity and
mortality as a result of both malnutrition and suicide. The seriousness of the disorder requires
extensive knowledge of effective treatment options. However, evidence for treatment efficacy in
this area is remarkably weak. A recent Cochrane review states that there is an urgent need for
large, well-designed treatment studies for patients with anorexia nervosa. The aim of this particular
multi-centre study is to evaluate the efficacy of two standardized outpatient treatments for patients
with anorexia nervosa: focal psychodynamic (FPT) and cognitive behavioural therapy (CBT). Each
therapeutic approach is compared to a "treatment-as-usual" control group.
Methods/Design: 237 patients meeting eligibility criteria are randomly and evenly assigned to the
three groups – two intervention groups (CBT and FPT) and one control group. The treatment
period for each intervention group is 10 months, consisting of 40 sessions respectively. Body
weight, eating disorder related symptoms, and variables of therapeutic alliance are measured during
the course of treatment. Psychotherapy sessions are audiotaped for adherence monitoring. The
treatment in the control group, both the dosage and type of therapy, is not regulated in the study
protocol, but rather reflects the current practice of established outpatient care. The primary
outcome measure is the body mass index (BMI) at the end of the treatment (10 months after
randomization).
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Discussion: The study design surmounts the disadvantages of previous studies in that it provides
a randomized controlled design, a large sample size, adequate inclusion criteria, an adequate
treatment protocol, and a clear separation of the treatment conditions in order to avoid
contamination. Nevertheless, the study has to deal with difficulties specific to the psychopathology
of anorexia nervosa. The treatment protocol allows for dealing with the typically occurring medical
complications without dropping patients from the protocol. However, because patients are difficult
to recruit and often ambivalent about treatment, a drop-out rate of 30% is assumed for sample size
calculation. Due to the ethical problem of denying active treatment to patients with anorexia
nervosa, the control group is defined as "treatment-as-usual".
Trial registration: Current Controlled Trials ISRCTN72809357
Background
Anorexia nervosa (AN) is a serious eating disorder marked
by pronounced, self-induced underweight. Diagnostic cri-
teria regarding weight are defined as maintenance of body
weight < 85% of expected weight, or a body mass index
(BMI) of < 17.5 kg/m2 (DSM-IV; ICD-10). Weight reduc-
tion is induced by abnormal food restriction with or with-
out purging behaviours such as self-induced vomiting,
compulsive exercise, and/or use of laxatives and diuretics;
other features include an intense fear of gaining weight
and a distorted body image. The average prevalence rate of
AN among young females is estimated to be 0.3% whereas
the prevalence in men is about ten times lower [1]. Several
long-term studies document the seriousness of anorexia
nervosa [2], concluding that about half the patients fully
recover from anorexia nervosa whereas a third improve
and 20% remain chronically ill [3]. In a 21-year follow-up
study of 84 patients, the crude mortality rate was 16%
with a standardized mortality rate of 9.8 [4,5].
In regard to treatment efficacy, the evidence to date is
judged to be weak [6]. In the guidelines of the British
National Institute of Clinical Excellence [7], treatment rec-
ommendations for anorexia nervosa are based solely on
expert reports and clinical experiences because clinical
studies of good quality are absent. To date, only a few
minor randomized controlled trials of individualized
adult outpatient therapy for anorexia nervosa exist [8,9].
The trials are barely comparable as different types of psy-
chotherapy and control groups were used. For instance,
results of the study of Dare et al. [10] found no difference
among the three specific therapies but showed that focal
psychotherapy and family therapy were more effective in
inducing weight gain than the control treatment (low-
contact outpatient management). One trial found that a
non-specific therapy was favoured over the two specific
psychotherapies (cognitive behaviour therapy and inter-
personal psychotherapy) [9]. However, no specific treat-
ment was identified that was consistently superior to any
other specific approach. Additionally, sample size in all
studies was very small. Hay et al. [8], in their systematic
review, therefore concluded that there is an urgent need
for large multi-centre trials of commonly used psycho-
therapies for adults with anorexia nervosa.
In spite of an absence of evidence, many treatment
approaches exist in clinical practice. In Germany, two
commonly used treatment approaches are psychody-
namic psychotherapy and cognitive behavioural therapy.
In patients with anorexia nervosa, psychodynamic ther-
apy addresses un- or pre-conscious conflicts that underlie
the disorder. A basic approach of psychodynamic treat-
ment in AN is to attend to the dysfunctional shaping of
relationships and structural deficits in regard to the regu-
lation of emotions that are relevant to the disordered eat-
ing behaviour [11]. Focal psychodynamic psychotherapy
(FPT) was developed as a standardised form of time-lim-
ited psychodynamic psychotherapy [12].
In the treatment of eating disorders, the aims of cognitive
behavioural therapy (CBT) focus on the modification of
behaviours and cognitions that maintain the existing
behaviour. Main foci are the modification of automatic
negative thoughts and dysfunctional assumptions that
relate to food, eating, weight, and body shape [13,14].
The aim of the ANTOP (Anorexia Nervosa Treatment of
OutPatients) study is the examination of the efficacy of
two standardised outpatient treatment programs for
patients with anorexia nervosa – focal psychodynamic
(FPT) and cognitive behavioural therapy (CBT) – in com-
parison to treatment-as-usual (TAU).
Methods
Study centres
This particular study is being carried out at 10 trial sites.
Participating centres are the Departments of Psychoso-
matic Medicine and Psychotherapy of the Universities of
Dortmund/Bochum, Erlangen, Essen, Freiburg, Ham-
burg, Heidelberg, München, Münster, Tübingen and
Ulm. Patients are recruited in the outpatient depart-
ments of the hospitals. To increase the number of eligi-
ble patients, the study is advertised in local as well as
regional media.Trials 2009, 10:23 http://www.trialsjournal.com/content/10/1/23
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Participants
Inclusion and exclusion criteria are listed in Table 1.
According to these criteria, the sample of patients
included in the study is representative of patients who
qualify for treatment in an outpatient setting who suffer
from either anorexia nervosa or subsyndromal anorexia
nervosa.
Interventions
Treatments for both the FPT and CBT groups are individ-
ual outpatient interventions, and are based on standard-
ised treatment manuals. In these groups, the therapy is
comprised of 40 sessions over a period of 10 months. This
fixed time frame was chosen in accordance with the usual
practice of the German health care system. CBT and FPT
are time-limited treatment approaches that have a main
advantage "to concentrate the mind of both the patient
and the therapist" [13]. At the same time, patients with
AN need a high intensity of treatment. Fairburn suggests a
total of 40 CBT sessions for AN patients with a BMI
between 15.0 and 17.5; this corresponds well to our study
sample.
The frequency of the sessions is shown in Figure 1:
FPT and CBT sessions are audiotaped to monitor adher-
ence to treatment manuals. Every ninth audiotape is
checked by monitors in Tübingen (CBT) or Heidelberg
(FPT) to ensure treatment integrity. To avoid contamina-
tion, the two treatments are provided by different thera-
pists. Treatment providers – psychologists or medical
doctors – are trained for a minimum of three years in the
respective psychotherapy methods and receive additional
training in the use of the manual. At every fourth session,
experienced supervisors provide supervision to the thera-
pists.
The psychodynamic treatment plan can roughly be subdi-
vided into three treatment phases. The first phase focuses
primarily on therapeutic alliance, ego-syntonicity of the
disorder, and self-esteem. In the second phase of treat-
ment, the main focus is placed on the association between
interpersonal relationships and eating (anorectic) behav-
iour. In the last phase, relevant aspects are the transfer to
everyday life, anticipation of treatment termination, and
parting.
The cognitive behavioural treatment plan also consists of
several treatment modules. The manual is based on the
work of Fairburn [13]. Work sheets are adapted to Legen-
bauer & Vocks [15]. At each session, homework, work
sheets, and exercises are assigned. The treatment plan
focuses on patients' education about underweight and
starvation as well as on the initiation and maintenance of
regular dietary habits and weight gain. Enhancement of
self-efficacy and self-monitoring are crucial elements of
the entire treatment process. Further details of the two
interventions are described in the treatment manuals [16].
The patients that are randomly assigned to the TAU con-
trol group receive support for further therapy planning.
The patients receive a list of established outpatient thera-
pists who practice psychotherapy in accordance with the
general German psychotherapy guidelines. This is the
standard approach for the allocation of patients to treat-
ment in the German health care system with its sectoral
separation of institutions that provide inpatient care and
of individual practitioners that provide outpatient care. In
the study protocol, the treatment (dosage and kind of
therapy) in the TAU arm is not regulated in order to get a
naturalistic and representative assessment of both the
usual outpatient care and the psychotherapeutic treat-
ment for patients with AN.
Table 1: Inclusion and exclusion criteria of the ANTOP study
Inclusion criteria ￿ AN and subsyndromal AN (lacking one diagnostic criterion according to DSM IV such as amenorrhea or weight phobia)
￿ Female
￿ Age 18 years or older
￿ 15.0 < BMI < 18.5 kg/m2
￿ written informed consent of the patient
Exclusion criteria ￿ Current substance abuse
￿ Current medication with neuroleptics
￿ Current suicidal ideation
￿ Psychotic disorder
￿ Bipolar disorder
￿ Serious unstable medical problems/complications
￿ Ongoing psychotherapy
￿ Pregnancy
￿ Clinically relevant cardiac arrhythmia
￿ Primary somatic diseaseTrials 2009, 10:23 http://www.trialsjournal.com/content/10/1/23
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Measurement time points
The time points of measurement are shown in Figure 2.
A three-month follow-up is included in the first funding
period of this study. Funding for a one-year follow-up has
been applied for.
Objectives and hypotheses
The objective of the current study is to assess whether two
psychotherapeutic interventions are more effective than
treatment-as-usual for the treatment of AN in adults. The
primary hypothesis has two parts: Part one states that
compared to treatment-as-usual, the specific psychothera-
peutic outpatient intervention FPT shows a better out-
come regarding the BMI at the end of treatment (T2). Part
two states that compared to treatment-as-usual, the spe-
cific psychotherapeutic outpatient intervention CBT
shows a better outcome regarding the BMI at the end of
treatment (T2). That is, the null hypotheses tested in the
confirmatory analysis are   and
 where μ denotes the expected BMI
value at the end of the respective treatment (T2), adjusted
for the pre-randomization baseline BMI (T0).
Secondary (explorative) hypotheses state: (1) that the spe-
cific interventions (FPT, CBT) do not differ in terms of
BMI increase at the end of treatment (T2); (2) that com-
pared to TAU, FPT shows a better outcome at the end of
treatment (T2) in regard to both a gain in quality of life
and other psychosocial variables; (3) that compared to
TAU, CBT shows a better outcome at the end of treatment
in regard to both a gain in quality of life and other psycho-
social variables.
Outcomes
The primary outcome measure is the body mass index
(BMI) at the end of the treatment (10 months after rand-
omization). Secondary outcome measures are: the Mor-
gan-Russell-criteria [17,18]; general axis I
psychopathology (SCID I) [19]; eating disorder specific
psychopathology (SIAB-Ex; Eating Disorder Inventory-2)
[20,21]; severity of depressive comorbidity (PHQ-9) [22];
and quality of life according to the SF-36 [23]. The thera-
peutic alliance is assessed by the Helping Alliance Ques-
tionnaire (HAQ) [24]. Table 2 shows the assessments and
outcome measurements at the different time points in the
study.
Outcome assessments are either self-reported or per-
formed by an independent blinded observer. Assessors are
trained at the beginning of the study. Blinding of the par-
ticipants is not possible.
Sample size calculation
Estimates of a clinically relevant effect size were derived
from two randomized controlled studies that evaluated
the effects of FPT and CBT in outpatients with AN [10,25].
Based on these findings, it was assumed that the different
interventions would result in an improvement of 1.0 BMI-
points compared to the TAU-group, with a pooled stand-
ard deviation of 1.7 BMI-points (effect size = 0.59). As the
hypothesis for the primary efficacy endpoint comprises
two statistical tests, namely FPT vs. TAU and CBT vs. TAU,
the nominal α-level was set to 2.5% (two-sided) in order
to restrict the Type 1 error level to 5%. Calculations were
H
FPT
FPT TAU 0 : mm =
H
CBT
CBT TAU 0 : mm =
Frequency of therapy sessions in the intervention conditions Figure 1
Frequency of therapy sessions in the intervention conditions. It has to be noted that a treatment period of 40 sessions 
does not equal always 10 months. We therefore defined the measurement point T2 as 10 months after inclusion in the study 
(± 2 weeks).
month  1 2 3 4 5 6 7 8 9 10
frequency 
of the 
sessions 
2 per 
week
2 per 
week
1 per 
week
1 per 
week
1 per 
week
1 per 
week
1/
two
weeks
1/
two
weeks
1/
two
weeks
1/
two
weeks
Time points of measurement in the ANTOP study Figure 2
Time points of measurement in the ANTOP study.Trials 2009, 10:23 http://www.trialsjournal.com/content/10/1/23
Page 5 of 7
(page number not for citation purposes)
done to detect an effect size of 0.59 for a comparison
power of 80%. Using a two-sample t-test, a sample size of
55 patients per treatment arm was required, resulting in a
total sample size of n = 3*55 = 165. Considering a non-
compliance and loss to follow up rate of 30% in total, a
minimum of 237 patients must be included in the study.
Randomization
Subjects are randomly assigned to the three groups. Rand-
omization is stratified by duration of AN, resulting in two
stratification groups. To ensure that allocation to the vari-
ous groups is concealed, a centralized randomization is
carried out by the Coordination Centre for Clinical Trials
(KKS) in Marburg, Germany. Eligibility assessment,
obtaining informed consent, and enrolling the patient in
the trial is done by the respective study centres. The infor-
mation data of the enrolled patient is transferred to the
KKS by fax.
Statistical analysis
At the conclusion of the study, intention to treat analyses
will be done. Missing values will be replaced by using the
Last Observation Carried Forward (LOCF) method. Addi-
tional sensitivity analyses using further imputation meth-
ods will also be done. For the primary analysis, both
experimental treatment groups (FPT and CBT) will be
compared with the TAU control group. The primary out-
come – BMI at T2 – will be analysed using a mixed mod-
elling approach. The grand mean, the treatment effects,
and the stratification variable will be designed as fixed
effects. The centre effect will be modelled as a random
effect. The baseline BMI is entered as covariate in the
model. The model can be written as:
where  Yijkl  denotes the BMI at T2 on the lth patient
 on treatment i (i = 1,2,3) in stratum j (j
= 1,2) in centre k (k = 1,...10), μ denotes the overall mean,
τi denotes the effect of the ith treatment, αj denotes the
effect of the jth stratum, ζk denotes the random effect of
the kth centre (ζj ~N(0, )),  β denotes the baseline cov-
ariate effect, Xl denotes the baseline BMI on the lth patient,
and εijkl denotes a residual error with εijkl ~ N(0,  ). The
parameters of interest in this confirmatory analysis are the
mean of the control group μ + τ1 and the contrasts of the
means τ2 - τ1 and τ3 - τ1 (that indicate the treatment effects
of FPT and CBT).
The secondary outcome measures will also be analysed
using mixed models. No interim or subgroup analyses are
planned.
Safety aspects
In AN patients, food restriction can lead to life threatening
starvation that requires inpatient medical monitoring and
treatment. As food restriction and severe weight loss are
central to the psychopathology of AN, an intermittent
inpatient treatment up to four weeks is not considered a
Serious Adverse Event (SAE). All other fatal or life-threat-
ening events are defined as SAE. SAEs have to be reported
immediately to the principal investigator and the central
YX ijkl i j k l ijkl =++ + + + mt a z b e,
( ,..., ) lL centrek =1
sz
2
s e
2
Table 2: Assessment of secondary outcome measures within the ANTOP study
Assessment
Point in study Expert rating Self-report
T0 SCID-I
SIAB-Ex
Morgan-Russell Outcome Assessment Schedule
EDI-2
PHQ-D
SF-36
T1 Morgan-Russell Outcome Assessment Schedule
T2 SCID-I
SIAB-Ex
Morgan-Russell Outcome Assessment Schedule
T3 Morgan-Russell Outcome Assessment Schedule
Monthly
(during the treatment phase)
HAQ
EDI-2: Eating Disorder Inventory-2; HAQ: Helping Alliance Questionnaire; PHQ-D: German version of the Patient Health Questionnaire; SCID-I: 
Structured Clinical Interview for DSM-IV Axis I Disorders; SF-36: Questionnaire on health-related quality of life; SIAB-Ex: Structured expert 
interview for anorectic and bulimic eating disordersTrials 2009, 10:23 http://www.trialsjournal.com/content/10/1/23
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ethics committee. All adverse events are documented and
reported to the principal investigator. An Independent
Safety Monitoring Board was implemented at the outset.
Medical complications
If, over the course of a two-week measurement period, a
patient of an intervention group (CBT, FPT) has a BMI <
14, the outpatient treatment is interrupted and the patient
is hospitalized. If the inpatient treatment leads to an
improvement within four weeks (BMI ≥ 14), the outpa-
tient treatment is resumed; if there is no improvement, the
patient is withdrawn from the intervention treatment.
Patients of the TAU-condition are advised to see their gen-
eral practitioner (GP) on a regular monthly basis to mon-
itor weight and possible medical complications. The study
staff is in contact with the GPs to arrange more intensive
treatment for the patient if necessary. Moreover, a control
of relevant blood parameters is also part of the diagnostic
measurement points (T0 – T3).
In the event of medical complications such as malnutri-
tion or the manifestation of a severe psychiatric disorder,
short-term hospitalization should be considered. For fur-
ther clinical decisions, the guidelines of the American Psy-
chiatric Association 2006 http://www.psych.org as well as
the recommendations of J. Treasure http://
www.iop.kcl.ac.uk/IoP/Departments/PsychMed/EDU/
downloads/pdf/RiskAssessment.pdf should be consid-
ered.
Discussion
The ANTOP study aims to provide new evidence about the
efficacy of two different therapy approaches in the outpa-
tient treatment of anorexia nervosa: focal psychodynamic
therapy and cognitive-behavioural therapy. The design of
the study overcomes the disadvantages of previous studies
in that it provides a randomized controlled design, a large
sample size, adequate inclusion criteria, an adequate
treatment protocol, and a clear separation of intervention
conditions.
This is the first multi-centre trial to include a sample size
of adults with AN that is large enough to detect a reason-
able effect size. The assumed drop-out rate of 30% is sim-
ilar to the drop-out rates of previous smaller trials. As the
assumed drop-out rate is quite high, special attention
must be given to the method of missing data imputation
in the data analysis. The ANTOP study is further distin-
guished from previous studies in that an adequate defini-
tion of inclusion criteria has been formulated. For
instance, McIntosh et al. [9] included patients with an
average BMI of 17.3; this made it difficult to generalize the
results to patients with AN. In the ANTOP study, the inclu-
sion criteria of having AN (or subsyndromal AN) and a
BMI between 15.0 and 18.5 kg/m2 ensure that the sample
of patients included in the study is representative. Further-
more, in contrast to the study of McIntosh et al. [9], the
various treatments are provided by different therapists to
avoid contamination.
Another noteworthy aspect of the study is the choice of
treatment-as-usual as a control condition. This was done
for several reasons. Studies that imposed a wait-list con-
trol condition in AN patients reported drop-out rates of
up to 70% [26]. In another trial, a control arm that used
dietary advice had a 73% overall treatment failure rate
[25]. Due to the ethical problem of denying active treat-
ment to AN patients, and considering the fact that the
health care system in Germany enables every AN patient
to get both in- and outpatient psychotherapy, it appeared
to be advisable to choose TAU as a control condition.
With this choice, the study faces the problem that thera-
peutic interventions in the TAU-condition could be quite
heterogeneous. In order to give consideration to this het-
erogeneity, the treatment dosage and approaches used in
the TAU-condition is documented in detail.
Specific challenges encountered by this outpatient study
were the definition of the outline and the boundaries of
treatment. In Germany, as in most health care systems,
patients with manifest AN are regularly offered inpatient
treatments – amongst others – to cope with potential
medical complications. In the ANTOP study, we specified
that a BMI over 15 was necessary for participation; also,
that either a drop of BMI below 14 or the occurrence of
medical complications would allow inpatient treatment
in regard to crisis intervention for up to four weeks as part
of the study protocol. This specification is the conclusion
of the results of previous studies that demonstrated the
necessity of developing treatment protocols that include
dealing with medical difficulties without dropping
patients from the protocol to which they were assigned
[27].
The principal investigators and leaders of the participating
centres of this particular study are, clinically speaking,
very experienced in the treatment of patients with AN. We
were therefore fully aware that in conducting this study we
would have to face numerous difficulties such as cancella-
tion of some therapy sessions, patient-initiated changes of
settings, drop-out rates, and medical complications. We
were also aware that many patients would not be cured
after the 10 months of outpatient treatments. Neverthe-
less, this is the first AN study where numerous methodo-
logical disadvantages were excluded from the outset. As a
result, it will improve the evidence-based knowledge
about outpatient treatment efficacy in patients with AN.
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